USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Innovation Waves in Immuno-oncology Therapy Development
Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development
12-Feb-2024
Global
Market Research
Immuno-oncology (I-O) therapies target tumors by harnessing the host’s immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.
Key questions answered in this study:
• What does the current clinical landscape of I-O therapies look like?
• Which are the technology enablers driving the adoption of I-O therapies?
• What are the key developments in adoptive cell therapies and cancer vaccines?
• What are the roadblocks to successful translation?
• What are the research and development (R&D) focus areas?
• What are the key focus areas for the future?
Why Is It Increasingly Difficult to Grow?The strategic imperative 8™: Factors creating pressure on growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Immuno-Oncology (I-O) Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Need for Immunotherapy
Scope of Analysis
Segmentation: Snapshot of I-O Therapies
I-O Therapies in Development
I-O Therapies in Development (continued)
Growth Opportunities in I-O Therapy
Growth Drivers
Growth Restraints
I-O Technology Trends and Developments
Trends in I-O Therapeutics
Therapeutic Development Trends in I-O
R&D Focus Areas to Boost Immunotherapies
Modulation of TME: Solid Tumor Type Determines Therapy
Developing Effective Preclinical Models for Translation
Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
Holistic Tumor Profiling to Boost Precision Oncology Efforts
Quick Facts on I-O Therapies
Clinical Development Landscape of I-O Therapies
Cell Therapy to Create the Next Wave of I-O Developments
Cell Therapy Types: Snapshot
Clinical Development Landscape of I-O Cell Therapies
Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
Next-generation CAR-T Therapy Development
Priority Areas to Improve the Accessibility of Cell Immunotherapy
Innovative Technologies for Cell Therapy Manufacturing and Delivery
Stakeholders Developing Emerging Next-gen Cell Therapies
Stakeholders Developing Emerging Next-en Cell Therapies (continued)
Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
Cancer Vaccine Types
Personalized Neoantigen Vaccines in Clinical Development
Personalized Neoantigen Vaccines in Clinical Development (continued)
Areas of Focus to Bolster Cancer Vaccine Development
RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
Road Ahead for Cancer Vaccines and Immunotherapy
Emerging Cancer Vaccine
Impact of Emerging Cancer Vaccines Across Cancers
Regional Trends in I-O Developments and Adoption
Federal Initiatives and Programs Driving I-O Therapy Development
I-O Deals and Investment Trends
Notable Partnerships and Collaborations in I-O, 2023
I-O: Current Gaps and Potential Opportunities
Strategies to Improve Access and Care Delivery of I-O Therapies
Growth Opportunity 1: Combination Immunotherapies
Growth Opportunity 1: Combination Immunotherapies (continued)
Growth Opportunity 2: Precision Oncology
Growth Opportunity 2: Precision Oncology (continued)
Growth Opportunity 3: Advanced Synthetic Biology Platforms
Growth Opportunity 3: Advanced Synthetic Biology Platforms (continued)
Growth Opportunity 4: Organoids and Organ-on-Chip Models
Growth Opportunity 4: Organoids and Organ-on-Chip Models (continued)
List of a Few Approved ADCs
Approved CAR-T Therapies (global)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| Author | Rruplekha Choudhurie |
| Industries | Chemicals and Materials |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Immuno-Oncology Industry Insights |
| Keyword 2 | Therapy Development Dynamics |
| Keyword 3 | Immuno-Oncology Market Analysis |
| Podcast | No |
| WIP Number | DAA2-01-00-00-00 |